Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds eukaryotic cell or component thereof or substance...
Reexamination Certificate
2006-04-18
2006-04-18
Huff, Sheela J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds eukaryotic cell or component thereof or substance...
C424S130100, C424S133100, C424S134100, C424S138100, C424S139100, C424S141100
Reexamination Certificate
active
07029677
ABSTRACT:
Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 antibodies provides a method of killing or inhibiting that growth of CD84HY1Protein-expressing cancer cells. Methods of immunotherapy and diagnosis of disorders associated with CD84Hy1protein-expressing cells are described.
REFERENCES:
patent: 01/79454 (2001-10-01), None
Dillman, J. Clinical Oncology, vol. 12, (7) pp. 1497-1515 (1994).
Waldmann, Science vol. 252 (1991) p. 1657.
Harris TIBTECH, vol. 11 p. 42 (1993).
Fundamental Immunology, 4th edition, ed. William Paul, pp. 58-59, 91-94 and 106-108) (1998).
Behr et al., Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy,Int. J. Cancer77:787-795 (1998).
Bottino et al., NTB-A, a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease,J. Exp. Med.194:235-246 (2001).
de la Fuente et al., CD84 leukocyte antigen is a new member of the Ig superfamily,Blood90:2398-2405 (1997).
Hornick et al., “Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or Interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties,”Blood89:4437-4447 (1997).
Jiang and Moller, “In vitro effects of HgCl2on murine lymphocytes. I. Preferable activation of CD4+ T cells in a responder strain,”J. Immunol.154:3138-3146 (1995).
Martin et al., “CD84 functions as a homophilic adhesion molecule and enhances IFN-γ secretion: Adhesion is mediated by Ig-like domain 1,”J. Immunol.167:3668-3676 (2001).
Ozaki, et al., “Immunotherapy of Multiple Myeloma With a Monoclonoal Antibody Directed Against a Plamsa Cell-Specific Antigen, HM1.24,”Blood90:3179-3186 (1997).
Racila et al., Detection and characterization of carcinoma cells in the blood,Proc. Natl. Acad. Sci. USA95:4589-4594 (1998).
Simpson et al., “Retinal VEGF mRNA measured by SYBR Green I fluorescence: A versatile approach to quantitative PCR,”Molec. Vision6:178-183 (2000).
Yang et al., “Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferators, perfluorooctanoic acid,”Int. Immunopharm.2:389-397 (2002).
“Approved Biotechnology Drugs,” Biotechnology Industry Drugs, printed Jan. 19, 2005.
Davis, et al., “Rituximab anti-CD20 monoclonal antibody therapy in Non-Hodgkin's Lymphoma: safety and efficacy of re-treatment,”J. Clin. Oncol.18:3135-3143 (2000).
Maloney, et al., “IDEC-C2B8 (Rituxi9mab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade Non-Hodgkin's Lymphoma,”Blood90:2188-2195 (1997).
Burk and Matuszewski, “Muromonab-CD3 and antithymocyte globulin in renal transplantation,”Ann. Pharacother.31:1370-1377 (1997).
White et al., “Antibody-targeted immunotherapy for treatment of malignancy,”Ann. Rev. Med.52:125-145 (2001).
Wilde and Goa, “Muromonab CD3: A reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection,”Drugs51:865-894 (1996).
Dedera Douglas
Emtage Peter C. R.
Wang Jian-Rui
Huff Sheela J.
Nuvelo, Inc.
Polizotto Renée S.
LandOfFree
Methods of therapy and diagnosis using immunotargeting of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of therapy and diagnosis using immunotargeting of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of therapy and diagnosis using immunotargeting of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3565008